Diagnosis and Treatment of Giant Cell Arteritis

被引:0
作者
Fabrizio Cantini
Laura Niccoli
Carlotta Nannini
Michele Bertoni
Carlo Salvarani
机构
[1] Hospital Misericordia e Dolce,2nd Division of Medicine, Rheumatology Unit
[2] Hospital S. Maria Nuova,Division of Rheumatology
来源
Drugs & Aging | 2008年 / 25卷
关键词
Giant Cell Arteritis; Temporal Artery; Axillary Artery; Superficial Temporal Artery; Polymyalgia Rheumatica;
D O I
暂无
中图分类号
学科分类号
摘要
Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10–15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroidsparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.
引用
收藏
页码:281 / 297
页数:16
相关论文
共 315 条
[21]  
Miranda-Filloy JA(2003)Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica Semin Arthritis Rheum 33 38-48
[22]  
Lopez-Diaz MJ(1996)Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of J Rheumatol 23 112-9
[23]  
Salvarani C(2000) infection Clin Exp Rheumatol 18 S12-4
[24]  
Macchioni P(1993)Human parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 11 309-13
[25]  
Zizzi F(2000)Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica Arthritis Rheum 43 1543-51
[26]  
Kobayashi S(1999)Detection of Arthritis Rheum 42 1255-8
[27]  
Yano T(2002) in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells Arthritis Rheum 46 3099-101
[28]  
Matsumoto Y(2002)The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation Arthritis Rheum 46 1056-60
[29]  
Gonzalez EB(2002)Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study Rheumatology (Oxford) 41 445-9
[30]  
Varner WT(1999)Temporal arteritis and J Rheumatol 26 361-9